Tyra Biosciences Reports Updates on TYRA-200 and TYRA-300 in P-I and P-I/II Trials for the Treatment of Solid Tumors
Shots:
- The company has dosed the 1st patient in the P-I (SURF201) trial evaluating the safety, tolerability, PK, MTD & preliminary antitumor activity of TYRA-200 in patients with unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma & other advanced solid tumors
- Tyra also provides updates on the P-I/II (SURF301) trial evaluating the MTD, RP2D, preliminary antitumor activity of TYRA-300 in patients with mUC, NMIBC & achondroplasia (results of P-I portion expected to be presented in 2024)
- The company also expects to initiate a P-II clinical trial evaluating the safety & tolerability of TYRA-300 in children (aged 5-12yrs.) with achondroplasia (IND submission to the US FDA to initiate the trial expected by H2'24)
Ref: Tyra Biosciences | Image: Tyra Biosciences
Related News:- GSK Signs a License Agreement with Hansoh Pharma for HS-20093 to Treat Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
